October, 2024
October 2024
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
We are Physicians, and the interest of patients should be our priority, summarised by Yakup Ergün
Oct 2, 2024, 15:22

We are Physicians, and the interest of patients should be our priority, summarised by Yakup Ergün

Yakup Ergün, Medical Oncologist at Bower Hospital, shared an article by Fred Saad on X:

The control arm of this study is ADT+PLACEBO. In the Materials and Methods section, it is stated that ‘this study was conducted in accordance with the principles of the Declaration of Helsinki. I do not believe that the researchers of this study, the members who provided ethical approval, and the Journal of Clinical Oncology editors are aware of the content of the Declaration of Helsinki.

Some points from the Declaration of Helsinki:

  • The Declaration of Geneva of the WMA binds the physician with the words, “The health of my patient will be my first consideration,” and the International Code of Medical Ethics declares that “A physician shall act in the patient’s best interest when providing medical care.”
  • It is the duty of the physician to promote and safeguard the health, well-being and rights of patients, including those who are involved in medical research. The physician’s knowledge and conscience are dedicated to the fulfilment of this duty.
  • Medical research is subject to ethical standards that promote and ensure respect for all human subjects and protect their health and rights.
  • While the primary purpose of medical research is to generate new knowledge, this goal can never take precedence over the rights and interests of individual research subjects.

Use of Placebo:

  • The benefits, risks, burdens and effectiveness of a new intervention must be tested against those of the best proven intervention(s), except in the following circumstances:
  • Where no proven intervention exists, the use of placebo, or no intervention, is acceptable.”

Title:Darolutamide in Combination with Androgen-Deprivation Therapy in Patients with Metastatic Hormone-Sensitive Prostate Cancer from the Phase III ARANOTE Trial

Authors: Fred Saad, Egils Vjaters, Neal Shore, David Olmos, Nianzeng Xing, Andrea Juliana Pereira de Santana Gomes, Augusto Cesar de Andrade Mota, Pamela Salman, Mindaugas Jievaltas, Albertas Ulys, Maris Jakubovskis, Evgeny Kopyltsov, Weiqing Han, Liina Nevalaita, Isabella Testa, Marie-Aude Le Berre, Iris Kuss and Kunhi Parambath Haresh

patients

Source: Yakup Ergün/X